hero-654791312-sized

Ensights

Science that is transforming lives and enabling the future

3 Questions to Ask When Choosing a Secondary Container for your Bulk Drug Substance

All Posts

3 Questions to Ask When Choosing a Secondary Container for your Bulk Drug Substance

Freezing down bulk drug substance (BDS) isn’t something you can play around with. This is a high value product where any failure or contamination due to the bag breaking can lead to delays in medicine getting to the patient. Making sure you pick the right solution to protecting that product makes a big difference.

Here are three questions you should be considering:

  1. How does this shell protect better than what I already have?
  2. Will this container maximize storage space in our freezer?
  3. How will this fit into my organization’s facility?

With large investments in drug development, a complex global supply chain and regulatory requirements, the journey to the patient is formidable. Next time you’re looking for a secondary BDS solution, ensure your manufacturer takes these factors into consideration:

Material Performance

  • Offering robust solutions that won’t comprise during a bag drop, throughout the freeze/thaw process and in transport that will meet performance demands.

Support and Flexibility

  • An applications engineering team, offering bespoke and off-the-shelf solutions to create end-to-end solutions committed to quick response times.

Supply

  • Having quick turnaround and availability for wide variety of offerings.

Cost

  • Looking at total value, how does the competition fare? Does the performance, support and supply compete?

Scalability

  • Providing reliable BDS freeze/thaw solutions allowing customers the ability to scale their operations from initial R&D evaluation to large scale production.

Trusted Partner

  • Having total support providing robust and reliable single-use solutions for bulk drug freeze thaw backed by a robust supply chain.

We understand the implications of a faulty container for your single-use solution and continue to work on ways to protect the integrity of product throughout the biopharma process. Ensure your next partner does the same.

For more information about our secondary containers and single-use solutions,
visit our website: cold-chain bioprocessing.  

Related Posts

How Does Quality by Design Affect Bulk Drug Cold Chain Manufacturing?

As a world-class supplier of advanced materials and process solutions for the semiconductor space, we understand the complexity and challenges of quality by design with respect to bulk drug cold chain manufacturing. Costly failures can be devastating and, in many cases, can be avoided by partnering with the correct single-use solutions provider to help optimize critical processes. When looking for solutions to protect your therapeutics during bulk drug cold chain, keep the following in mind:

Discussion of Freeze/Thaw Workflows

Meet Regulatory Requirements to Ensure Patient Safety Developing and validating a robust freeze/thaw process while meeting regulatory guidelines is a multifaceted challenge. The demand for cold chain processes and operations for biopharma products is increasing due to scaling of complex therapeutics, a challenging global supply chain, and growing shipping complexities. Ensuring compliance throughout the product journey is integral to mitigating risk for product loss and contamination.

Benchmarks Bridge the Semiconductor Yield and Reliability Performance Gap in the Automotive Domain

A major difference exists as more features from our smartphones are integrated, replicated, and expanded in our cars - reliability expectations. A smartphone is designed to work effectively for 3-5 years while cars expect 10-15 years with standard maintenance. Failure in our cars can create dangerous situations for drivers, passengers, and others on the roadway. Designing and manufacturing our cars to ensure the functional safety along with the performance expectations of our new digital transportation systems is challenging manufacturing models for carmakers.